Terry Hardy
Lung cancer remains one of the most prevalent and deadliest malignancies worldwide, contributing significantly to cancer-related morbidity and mortality. Traditional treatment approaches have primarily focused on generalized therapies that may not be optimally effective for all patients due to the inherent heterogeneity of lung cancer. However, advancements in genomic profiling and personalized medicine have opened new avenues for tailoring treatment strategies to individual patients, enhancing treatment outcomes and potentially revolutionizing the landscape of pulmonary cancer treatment.
Comparte este artículo
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 